STARLING ONCOLOGY INC

STLNNASDAQ

🏆 #2779 by market capEarnings Nov 11US Equity

$574.07▼ $33.07 (−5.76%)

Simulated price

🔔

Track STLN

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 5.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$651M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

15.7%

Thin

💵FCF Margin

-0.6%

Thin

⚖️P/S Ratio

1.1x

Cheap

Otter Score

Fair

No chart data available for STLN.

Trading Snapshot

Day Range: $570.77 – $578.87
52-Week Range: $2.32 – $7.13
Volume: $2.98B
Avg Volume: $2.03B
Shares Outstanding: 100.0M
Next Earnings: Oct 28, 2026

Fundamentals Snapshot

Annual Revenue: $503M
Last Q Revenue: $161M
P/E Ratio: -21.7
P/S Ratio: 1.1x
EPS (TTM): $-0.35
Dividend Yield: 0.00%

Why Investors Own STLN

✓High-growth profile — revenue up +15.6% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

STARLING ONCOLOGY INC

STLN

Financial Trends

Revenue (TTM)

$503M▲ +10.1% YoY

Gross Margin (TTM)

50.8%▲ +2.5% YoY

Operating Income (TTM)

$140M▲ +10.1% YoY

Free Cash Flow (TTM)

$68M▲ +10.1% YoY

StockOtter · stockotter.space

About STARLING ONCOLOGY INC

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

🦦